Thilo Schroeder

Thilo Schroeder is a seasoned professional in the venture capital and private equity industry, currently serving as a Partner at Nextech Invest Ltd. since July 2012, focusing on global oncology investments. Schroeder holds significant leadership roles as a board member or observer for multiple organizations, including Synnovation Therapeutics, Alterome Therapeutics, Exo Therapeutics, Atavistik Bio, MOMA Therapeutics, Circle Pharma, and REVOLUTION Medicines. Educational qualifications include a PhD in Biochemistry from the University of Zurich, a degree in Biotechnology from ESBS, and various other credentials in molecular biology and life sciences from prestigious institutions.